Earnings Call Summary | Tracon Pharmaceuticals(TCON.US) Q1 2024 Earnings Conference
Earnings Call Summary | Tracon Pharmaceuticals(TCON.US) Q1 2024 Earnings Conference
The following is a summary of the TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript:
以下是TRACON製藥公司（TCON）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
TRACON's R&D expenses were down to $1.9 million in Q1 2024 from $5 million in Q1 2023 due to the termination of a pivotal trial.
General and administrative expenses decreased to $1.4 million from $2.3 million in Q1 2023 due to lower legal expenses.
Net loss was $3.2 million in Q1 2024, down from $8.5 million in Q1 2023.
$8 million in cash and cash equivalents held in March 2024.
由於一項關鍵試驗的終止，TRACON的研發費用從2023年第一季度的500萬美元降至2024年第一季度的190萬美元。
由於法律費用減少，一般和管理費用從2023年第一季度的230萬美元降至140萬美元。
2024年第一季度的淨虧損爲320萬美元，低於2023年第一季度的850萬美元。
2024年3月持有的800萬美元現金及現金等價物。
Business Progress:
業務進展：
Progress is sustained with the ongoing Phase II ENVASARC pivotal trial which is expected to conclude by Q3.
TRACON expects Fast Track designation for ENVA in certain sarcoma subtypes.
Development of clinical strategy for approval of ENVA in frontline sarcoma is ongoing.
An ongoing Phase II trial, sponsored by NCI, is assessing TRACON's DNA damage repair inhibitor TRC102 in Stage III non-small cell lung cancer.
The company licensed their PDP for $3 million upfront payment to a biotech company last year and plans on evaluating more drug candidates.
TRACON is considering options to meet NASDAQ's equity requirement by June 30, 2024.
正在進行的ENVASARC二期關鍵試驗持續取得進展，該試驗預計將於第三季度結束。
TRACON預計，某些肉瘤亞型中的ENVA被指定爲快速通道。
批准ENVA用於一線肉瘤的臨床策略正在制定中。
由NCI贊助的一項正在進行的二期試驗正在評估TRACON在第三期非小細胞肺癌中的DNA損傷修復抑制劑 TRC102。
該公司去年以300萬美元的預付款向一家生物技術公司許可了他們的PDP，並計劃評估更多的候選藥物。
TRACON正在考慮在2024年6月30日之前滿足納斯達克股票要求的期權。
More details: Tracon Pharmaceuticals IR
更多詳情： Tracon 製藥 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。